-
The challenge of improving infection prevention is a formidable one, given such basic conundrums as how do you effectively isolate an infected or colonized resident who needs to move about and socialize for their overall health and well-being?
-
Fifteen percent of U.S. nursing homes receive deficiency citations for infection control per year, with many of those breaches tied to staffing issues, long term care researchers report.
-
Though conceding that powdered latex gloves pose little risk of causing patient infections, the nation's largest infection prevention group is joining the chorus of those urging the Food and Drug Administration to ban the gloves in favor of safer alternatives.
-
There are obvious challenges that run through the training of an Infection Preventionist (IP) and fortunately many have answers with solid references.
-
Stacey Taylor RN,BSN, entered her job as a rookie infection preventionist with much more optimism than experience, ready to take on a new role she saw as both interesting and important.
-
As infection control and prevention in long term care settings becomes a national priority, a little state may provide some key answers to a big problem: the spread of multidrug resistant organisms (MDROs) across the healthcare continuum.
-
The Association for Professionals in Infection Control and Epidemiology (APIC) is tracking a growing body of proposed state legislation related to infection prevention in long term care. A selection of state bills proposed this year include the following:
-
Though there was considerable pushback from infection preventionists when the idea of a federal infectious disease standard was proposed last year, recent comments from the chief of OSHA reveal that the controversial regulation is still on the agenda.
-
Uldrick et al performed a pilot study in which 14 HIV-infected patients with symptomatic MCD received high-dose AZT (600 mg PO Q6 hours) and VGC (900 mg PO Q12 hours).
-
In this issue: Calcium supplements and MI; birth control pills and VTE; ACE inhibitors and breast cancer risk; spending on pharmaceuticals; and FDA actions.
